Lars Harbaum
Overview
Explore the profile of Lars Harbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hennigs J, Oqueka T, Harbaum L, Klose H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
. 2022 Mar;
65(4):462-470.
PMID: 35294563
Organ-specific sequelae after COVID-19 occur frequently and are highly diverse in their features. Sequelae and symptoms persisting for more than four weeks after COVID-19 define the condition "long COVID."Organ-specific sequelae...
12.
Rhodes C, Wharton J, Swietlik E, Harbaum L, Girerd B, Coghlan J, et al.
Am J Respir Crit Care Med
. 2022 Jan;
205(9):1102-1111.
PMID: 35081018
NT-proBNP (N-terminal pro-brain natriuretic peptide), a biomarker of cardiac origin, is used to risk stratify patients with pulmonary arterial hypertension (PAH). Its limitations include poor sensitivity to early vascular pathology....
13.
Wilkins M, Mckie M, Law M, Roussakis A, Harbaum L, Church C, et al.
Pulm Circ
. 2021 Dec;
11(4):20458940211052823.
PMID: 34868551
Pulmonary arterial hypertension is an unmet clinical need. Imatinib, a tyrosine kinase inhibitor, 200 to 400 mg daily reduces pulmonary artery pressure and increases functional capacity in this patient group,...
14.
Yogeswaran A, Tello K, Lund J, Klose H, Harbaum L, Sommer N, et al.
J Heart Lung Transplant
. 2021 Dec;
41(3):400-410.
PMID: 34857454
Background: γ-glutamyl transferase (GGT), the aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, and the neutrophil-to-lymphocyte ratio (NLR) are prognostic biomarkers in several cardiovascular diseases, but their relevance in pulmonary hypertension (PH) is...
15.
Qaderi V, Weimann J, Harbaum L, Schrage B, Knappe D, Hennigs J, et al.
J Clin Med
. 2021 Nov;
10(21).
PMID: 34768652
Background: Right ventricular dysfunction is a major determinant of outcome in pulmonary arterial hypertension (PAH). We aimed to identify echocardiographic right heart parameters associated with adverse outcome and to develop...
16.
Toshner M, Church C, Harbaum L, Rhodes C, Villar Moreschi S, Liley J, et al.
Eur Respir J
. 2021 Sep;
59(3).
PMID: 34588193
Background: Inflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling. Methods: We conducted a...
17.
Harbaum L, Hennigs J, Simon M, Oqueka T, Watz H, Klose H
Respir Res
. 2021 Jul;
22(1):199.
PMID: 34233669
Background: Observational studies on the general population have suggested that airflow obstruction associates with left ventricular (LV) filling. To limit the influence of environmental risk factors/exposures, we used a Mendelian...
18.
Hannemann J, Glatzel A, Hillig J, Zummack J, Schumacher U, Luneburg N, et al.
Front Physiol
. 2020 Dec;
11:597559.
PMID: 33281630
Chronic hypoxia causes pulmonary vasoconstriction leading to pulmonary hypertension and right ventricular hypertrophy. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis; its level increases in hypoxia...
19.
Hoeper M, Pausch C, Grunig E, Klose H, Staehler G, Huscher D, et al.
J Heart Lung Transplant
. 2020 Oct;
39(12):1435-1444.
PMID: 33082079
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients....
20.
Yogeswaran A, Gall H, Tello K, Grunig E, Xanthouli P, Ewert R, et al.
Pulm Circ
. 2020 Aug;
10(3):2045894020941682.
PMID: 32754309
Pulmonary hypertension is frequently underdiagnosed, and referral is delayed with subsequent impact on outcomes. During the SARS-CoV-2 pandemic, restrictions on daily life and changes in hospitals' daily routine care were...